Scientists and animal‑welfare advocates press committee for non‑animal test methods for cosmetics, household products
Loading...
Summary
Supporters of S.640 / H.989 told the committee the bills would require use of validated non‑animal test methods for cosmetics and household product safety assessments when alternatives exist; biomedical research exemptions and implementation details were discussed.
The committee heard testimony in favor of S.640 and H.989, bills that would require manufacturers and testing facilities to use non‑animal alternatives for cosmetics, household cleaners and certain industrial chemicals when validated alternatives are available.
Supporters — representing Humane World for Animals, Animal Defenders International, medical professionals and students — argued traditional animal tests are scientifically limited and that modern human‑relevant technologies provide faster, cheaper and often more predictive safety data. Michelle Shaw, senior program manager at Humane World for Animals, said non‑animal technologies "can deliver results in hours or days, while animal tests can take months or years to complete with less predictive data." Other witnesses pointed to Massachusetts companies developing non‑animal platforms and to cosmetics brands using cruelty‑free methods.
Speakers emphasized the bills explicitly exempt medical and pharmaceutical research. Several witnesses also urged the committee to allow the Department of Public Health or other state agencies to promulgate implementing regulations and validation criteria, and to specify that contract testing facilities are included in the law to avoid loopholes.
Opposition testimony from biomedical research advocates raised concerns that language must be carefully drafted so that exemptions for medical research are clear and so that legitimate preclinical safety testing is not unintentionally restricted. The Massachusetts Society for Medical Research requested that the committee study the bill further and refine language to eliminate unintended restrictions on biomedical research institutions.
No committee vote was taken. Supporters asked the committee to report the bill favorably and offered to provide technical regulatory language to ensure the bill’s medical exemptions and implementation pathways are clear.
